{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yang HJ"],"funding":["\"Food Functionality Evaluation program\" under the Ministry of Agriculture, Food and Rural Affairs and partly the Korea Food Research Institute."],"pagination":["3751"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11547720"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(21)"],"pubmed_abstract":["<h4>Background/objectives</h4><i>Schisandra chinensis</i> Fructus (SCF) is a traditional medicinal herb containing lignans that improves glucose metabolism by mitigating insulin resistance. We aimed to investigate the therapeutic potential and action mechanism of SCF for Alzheimer's disease (AD) using a network pharmacology analysis, followed by experimental validation in an AD rat model.<h4>Methods</h4>The biological activities of SCF's bioactive compounds were assessed through a network pharmacology analysis. An AD rat model was generated by infusing amyloid-β peptide (Aβ) (25-35) into the hippocampus to induce Aβ accumulation. The AD rats were fed either 0.5% dextrin (AD-Con) or 0.5% SCF (AD-SCF group) in a high-fat diet for seven weeks. The rats in the normal/control group received an "],"journal":["Nutrients"],"pubmed_title":["Efficacy and Mechanism of &lt;i&gt;Schisandra chinensis&lt;/i&gt; Fructus Water Extract in Alzheimer's Disease: Insights from Network Pharmacology and Validation in an Amyloid-β Infused Animal Model."],"pmcid":["PMC11547720"],"funding_grant_id":["2023-2"],"pubmed_authors":["Zhang T","Jang DJ","Kim MJ","Hur HJ","Park S","Yang HJ","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Mechanism of &lt;i&gt;Schisandra chinensis&lt;/i&gt; Fructus Water Extract in Alzheimer's Disease: Insights from Network Pharmacology and Validation in an Amyloid-β Infused Animal Model.","description":"<h4>Background/objectives</h4><i>Schisandra chinensis</i> Fructus (SCF) is a traditional medicinal herb containing lignans that improves glucose metabolism by mitigating insulin resistance. We aimed to investigate the therapeutic potential and action mechanism of SCF for Alzheimer's disease (AD) using a network pharmacology analysis, followed by experimental validation in an AD rat model.<h4>Methods</h4>The biological activities of SCF's bioactive compounds were assessed through a network pharmacology analysis. An AD rat model was generated by infusing amyloid-β peptide (Aβ) (25-35) into the hippocampus to induce Aβ accumulation. The AD rats were fed either 0.5% dextrin (AD-Con) or 0.5% SCF (AD-SCF group) in a high-fat diet for seven weeks. The rats in the normal/control group received an ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2025-04-18T14:07:21.271Z","creation":"2025-04-07T00:04:21.436Z"},"accession":"S-EPMC11547720","cross_references":{"pubmed":["39519586"],"doi":["10.3390/nu16213751"]}}